Company intelligence / Profile preview

Visum Prius

Ownership: Private
Development stage: Other

Overview

Visum Prius is an early-stage biotechnology company focused on developing innovative therapies for ophthalmic diseases. The company's primary research efforts are directed toward addressing high-need areas in retinal health, specifically targeting conditions like age-related macular degeneration and diabetic macular edema. By leveraging specialized drug delivery and molecular targeting, Visum Prius aims to improve visual outcomes and treatment durability for patients. The company is currently advancing its lead candidates through pre-clinical validation to support future clinical development.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Visum Prius.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Visum Prius.

Explore the full profile